drugset
drugset / Trial / NCT03556683

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

NCT03556683 ↗

Completed 24 enrolled University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI) · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.

Timeline

Start
2018-10-01
Primary completion
2024-06-06
Completion
2024-06-06

Drugs

EvaluationDrugModalityDoseRoute
Background Salbutamol Unknown 90 ug —

Indications

asthma